Literature DB >> 2181382

Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

N R Lemoine1, S Staddon, C Dickson, D M Barnes, W J Gullick.   

Abstract

The rat neu proto-oncogene, which is a putative growth factor receptor closely related to the epidermal growth factor receptor, can be activated in vivo by a single point mutation in the sequence encoding its transmembrane region. The human homologue of neu, c-erbB-2, can be activated in vitro to an oncogenic form by point mutations in the same relative position in the gene. We have sought the presence of such activating mutations in a series of 100 cases of human breast cancer by polymerase chain reaction amplification and sequence-specific oligonucleotide hybridization, and also by a designed restriction fragment length polymorphism strategy in cases with Southern blot evidence of c-erbB-2 amplification. No evidence of activating point mutations in the c-erbB-2 protooncogene was found in any of these cases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181382

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 2.  Her-2 targeted therapy: beyond breast cancer and trastuzumab.

Authors:  Keith T Flaherty; Marcia S Brose
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

3.  Identification and characterization of a novel enhancer for the rat neu promoter.

Authors:  D H Yan; M C Hung
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

Review 4.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

Review 5.  Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer.

Authors:  W J Muller
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

6.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

7.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.

Authors:  Wanping Xu; Monica Marcu; Xitong Yuan; Edward Mimnaugh; Cam Patterson; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

Authors:  C T Guy; M A Webster; M Schaller; T J Parsons; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.

Authors:  Eran R Andrechek; William R Hardy; Michael A Laing; William J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.